DE69838720D1 - Lipoprotein-regulierende arzneimittel - Google Patents

Lipoprotein-regulierende arzneimittel

Info

Publication number
DE69838720D1
DE69838720D1 DE69838720T DE69838720T DE69838720D1 DE 69838720 D1 DE69838720 D1 DE 69838720D1 DE 69838720 T DE69838720 T DE 69838720T DE 69838720 T DE69838720 T DE 69838720T DE 69838720 D1 DE69838720 D1 DE 69838720D1
Authority
DE
Germany
Prior art keywords
lsr
purified
ffa
isolated
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838720T
Other languages
English (en)
Other versions
DE69838720T2 (de
Inventor
Bernard Bihain
Lydie Bougueleret
Frances Yen-Potin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Merck Biodevelopment SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Serono Genetics Institute SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9710088A external-priority patent/FR2767136B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Serono Genetics Institute SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of DE69838720D1 publication Critical patent/DE69838720D1/de
Application granted granted Critical
Publication of DE69838720T2 publication Critical patent/DE69838720T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69838720T 1997-08-06 1998-08-06 Lipoprotein-regulierende arzneimittel Expired - Lifetime DE69838720T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9710088A FR2767136B1 (fr) 1997-08-06 1997-08-06 Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
FR9710088 1997-08-06
FR9805032A FR2767135B1 (fr) 1997-08-06 1998-04-22 Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
FR9805032 1998-04-22
PCT/IB1998/001256 WO1999007736A2 (en) 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments

Publications (2)

Publication Number Publication Date
DE69838720D1 true DE69838720D1 (de) 2007-12-27
DE69838720T2 DE69838720T2 (de) 2008-10-30

Family

ID=26233732

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69838720T Expired - Lifetime DE69838720T2 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende arzneimittel
DE69820419T Expired - Lifetime DE69820419T2 (de) 1997-08-06 1998-08-06 Klonierung und verwendung des lsr-rezeptors
DE69841186T Expired - Lifetime DE69841186D1 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende Medikamente

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69820419T Expired - Lifetime DE69820419T2 (de) 1997-08-06 1998-08-06 Klonierung und verwendung des lsr-rezeptors
DE69841186T Expired - Lifetime DE69841186D1 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende Medikamente

Country Status (13)

Country Link
US (8) US6635431B1 (de)
EP (4) EP1375516A3 (de)
JP (3) JP3726969B2 (de)
AT (3) ATE443721T1 (de)
AU (2) AU745607C (de)
CA (2) CA2298849A1 (de)
CY (1) CY1107808T1 (de)
DE (3) DE69838720T2 (de)
DK (2) DK1003783T3 (de)
ES (2) ES2210786T3 (de)
FR (1) FR2767135B1 (de)
PT (2) PT1003783E (de)
WO (2) WO1999007737A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) * 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
CA2348828C (en) 1998-11-04 2009-09-15 Genset S.A. Genomic and complete cdna sequences of apm1 and biallelic markers thereof
ATE427362T1 (de) 1999-02-10 2009-04-15 Serono Genetics Inst Sa Polymorphe marker des lsr-gens
MXPA01010550A (es) * 1999-04-20 2002-06-04 Zymogenetics Inc Proteina homologa zacrp3 relacionada al complemento de adipocitos.
EP1171599A1 (de) * 1999-04-20 2002-01-16 ZymoGenetics, Inc. Zacrp2: homolog des adipozyten komplement verwandten proteins
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2001032868A1 (en) * 1999-11-04 2001-05-10 Genset Apm1 biallelic markers and uses thereof
US7338787B2 (en) * 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
AU785090B2 (en) * 2000-01-14 2006-09-14 Serono Genetics Institute S.A. OBG3 globular head and uses thereof for decreasing body mass
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US20020058617A1 (en) * 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
ATE464378T1 (de) * 2000-05-31 2010-04-15 Serono Genetics Inst Sa Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und - differenzierung
IL153927A0 (en) * 2000-07-18 2003-07-31 Genset Sa Genomic maps comprising biallelic markers, new such markers and the use of biallelic markers
CA2439116A1 (en) * 2001-02-26 2002-09-06 The University Of Sydney Method of improving the growth performance of an animal
WO2002072149A1 (en) * 2001-03-14 2002-09-19 Oklahoma Medical Research Foundation Methods for reducing fat by administration of adiponectin
JP4547696B2 (ja) * 2001-06-07 2010-09-22 第一三共株式会社 肝硬変予防・治療剤
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1418934A1 (de) * 2001-08-02 2004-05-19 Genset S.A. Agonisten und antagonisten von xobesin zur behandlung von stoffwechselerkrankungen
WO2003041738A1 (en) * 2001-11-15 2003-05-22 Genset S.A. Treatment of metabolic disorders with xitar agonists and antagonists
EP1448226A1 (de) * 2001-11-29 2004-08-25 Genset S.A. Agonisten und antagonisten prolixin zur behandlung von stoffwechselerkrankungen
EP1474445A4 (de) * 2002-01-18 2007-02-21 Protemix Corp Ltd Glykoisoformen vom adiponektin und deren verwendung
US6852693B2 (en) 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans
JP4147220B2 (ja) * 2002-05-24 2008-09-10 独立行政法人科学技術振興機構 動脈硬化症予防治療薬
ATE478890T1 (de) 2002-05-31 2010-09-15 Serono Genetics Inst Sa Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon
DE602004022632D1 (de) * 2003-01-09 2009-10-01 Beth Israel Hospital Verwendung von adiponectin zur diagnose von krebs
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US7931693B2 (en) * 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
EP1830873A4 (de) * 2004-12-10 2008-04-02 Protemix Corp Ltd Glyponectin (glykosyliertes adiponektin) zur behandlung von krankheiten und zuständen
US7592423B2 (en) * 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
EP1833845A2 (de) * 2005-01-07 2007-09-19 Xencor Adiponectinvarianten
US7678886B2 (en) * 2005-01-07 2010-03-16 Xencor, Inc. Pharmaceutical compositions of adiponectin variants and methods of storage
US7749956B2 (en) * 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
WO2006104964A2 (en) * 2005-03-28 2006-10-05 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30
US20070054359A1 (en) * 2005-07-11 2007-03-08 Jonathan Zalevsky Rational Chemical Modification of Adiponectin Variants
CA2616912A1 (en) * 2005-07-29 2007-02-08 Laboratoires Serono S.A. Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
US9060835B2 (en) 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US20110137227A1 (en) * 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
PL2238458T3 (pl) * 2007-12-19 2012-03-30 Lilly Co Eli Sposób przewidywania odpowiedzi na terapię farmaceutyczną otyłości
JP5429736B2 (ja) * 2009-04-13 2014-02-26 国立大学法人神戸大学 タイトジャンクション調節剤
CA2830923A1 (en) * 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN104024276A (zh) * 2012-06-21 2014-09-03 卡姆普根有限公司 Lsr抗体及其用于癌症治疗的用途
CN104004066B (zh) * 2013-02-26 2017-05-31 上海市第一人民医院 预防或抑制炎症反应和血管新生的小分子多肽及其应用
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
WO2015098113A1 (ja) 2013-12-27 2015-07-02 独立行政法人医薬基盤研究所 悪性腫瘍の治療薬

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US67881A (en) * 1867-08-20 Geobge p
US111500A (en) * 1871-01-31 Improvement in repeating fire-arms
US77051A (en) * 1868-04-21 peters
US5543394A (en) * 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
NL9100132A (nl) * 1991-01-25 1992-08-17 Ingeny Bv Werkwijze voor het detecteren van dna sequentievariatie.
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
FR2733762B1 (fr) 1995-05-02 1997-08-01 Genset Sa Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US5869330A (en) * 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
CA2244693A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US6116126A (en) 1996-07-10 2000-09-12 Van Den Bulcke; Marc Method and machine for making profile pieces
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
EP0941366A2 (de) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelische marker
ES2264207T3 (es) * 1997-07-18 2006-12-16 Zymogenetics, Inc. Homonologos proteinicos especificos de adipocitos.
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
AU744254B2 (en) 1997-08-26 2002-02-21 Zymogenetics Inc. Adipocyte-specific protein homologs
EP1033134B8 (de) 1997-10-29 2007-09-19 Otsuka Pharmaceutical Co., Ltd. Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6579852B2 (en) * 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030215836A1 (en) 2000-03-17 2003-11-20 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
WO2003011324A1 (en) 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1418934A1 (de) 2001-08-02 2004-05-19 Genset S.A. Agonisten und antagonisten von xobesin zur behandlung von stoffwechselerkrankungen
EP1448226A1 (de) 2001-11-29 2004-08-25 Genset S.A. Agonisten und antagonisten prolixin zur behandlung von stoffwechselerkrankungen

Also Published As

Publication number Publication date
US6635431B1 (en) 2003-10-21
WO1999007736A2 (en) 1999-02-18
ES2210786T3 (es) 2004-07-01
PT964870E (pt) 2004-02-27
US6344441B1 (en) 2002-02-05
US20080249009A1 (en) 2008-10-09
US7291709B2 (en) 2007-11-06
EP1375516A3 (de) 2004-06-09
JP2005143508A (ja) 2005-06-09
ATE256146T1 (de) 2003-12-15
CY1107808T1 (el) 2013-06-19
JP2001512746A (ja) 2001-08-28
WO1999007737A2 (fr) 1999-02-18
WO1999007736A3 (en) 1999-05-20
EP1903057A2 (de) 2008-03-26
FR2767135A1 (fr) 1999-02-12
US7919091B2 (en) 2011-04-05
DE69838720T2 (de) 2008-10-30
DE69820419T2 (de) 2004-11-25
FR2767135B1 (fr) 2002-07-12
AU754942B2 (en) 2002-11-28
EP1003783B1 (de) 2007-11-14
US20020151498A1 (en) 2002-10-17
WO1999007737A3 (fr) 1999-06-10
DK0964870T3 (da) 2004-03-08
EP0964870A2 (de) 1999-12-22
ATE378354T1 (de) 2007-11-15
JP2001512492A (ja) 2001-08-21
JP3726969B2 (ja) 2005-12-14
DK1003783T3 (da) 2008-01-02
US20110165166A1 (en) 2011-07-07
DE69841186D1 (de) 2009-11-05
EP1903057B1 (de) 2009-09-23
EP1903057A3 (de) 2008-06-25
PT1003783E (pt) 2007-12-06
ATE443721T1 (de) 2009-10-15
US6946444B2 (en) 2005-09-20
CA2298849A1 (en) 1999-02-18
US20090263847A1 (en) 2009-10-22
US20040077051A1 (en) 2004-04-22
DE69820419D1 (de) 2004-01-22
AU745607C (en) 2002-08-29
US20020165154A1 (en) 2002-11-07
US7220722B2 (en) 2007-05-22
AU745607B2 (en) 2002-03-21
EP1003783A2 (de) 2000-05-31
AU8556398A (en) 1999-03-01
CA2274302A1 (fr) 1999-02-18
EP1375516A2 (de) 2004-01-02
EP0964870B1 (de) 2003-12-10
ES2296339T3 (es) 2008-04-16
AU8556498A (en) 1999-03-01

Similar Documents

Publication Publication Date Title
DE69838720D1 (de) Lipoprotein-regulierende arzneimittel
ATE444361T1 (de) Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
ATE25197T1 (de) Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
FI104180B1 (fi) Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
HUP0001650A2 (hu) Javított expressziós vektorok
DE69738432D1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
DK1860187T3 (da) Apo-2-receptor
DK230683A (da) Rekombinante dna-klonende vektorer til udtrykkelse af endogent protein
NO864139L (no) Polypeptid virksomt ved dannelse av aids-antistoff.
DK1017715T3 (da) Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
DE59814354D1 (de) Zellvolumenregulierte humane Kinase h-sgk
ATE323764T1 (de) Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
DE68914345D1 (de) Gamma-atriales, natriuretisches Polypeptid erkennende monoklonale Antikörper, solche Antikörper produzierende Hybridome und deren Herstellung und Verwendung.
Chuba Susceptibility of Monoclonal IGG Paraproteins to Plasmic Cleavage Using Glycerin Stabilized Human Plasmin
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
ATE382059T1 (de) Neue humane androgenrezeptor-varianten
ATE335005T1 (de) Menschliches protein mit in vitro antiproliferativer aktivität.
DE69032096D1 (de) Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte
DE69736325D1 (de) Cr1 fragmente und deren verwendung
PT1241185E (pt) Acido nucleico que e amplificado em tumores humanos e materiais e metodos relacionados
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder
ATE28450T1 (de) (alkylsulfonyl)methansulfonate als antikrebsmittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition